国内首例经导管主动脉瓣置入Edwards SAPIEN 3瓣膜
|
摘要
<正>经导管主动脉瓣置入术(transcatheteraorticvalve implantation, TAVI)是主动脉瓣狭窄的有效治疗手段,已成为外科主动脉瓣置换术手术禁忌或高危患者的一线治疗手段。在我国,TAVI正在逐步开展,普遍使用的是国产自膨胀式瓣膜[1]。随着人工瓣膜器械的不断改良,爱德华瓣膜公司(Edwards Lifescience)也推出了SAPIEN系列的最新一代产品SAPIEN 3。SAPIEN 3的低瓣周漏发生率、低血管并发症发生率及低死亡率已在多项国际临床研究中得到证实[2-3]。
引文
[1]中国医师协会心血管内科医师分会结构性心脏病专业委员会,中华医学会心血管病学分会结构性心脏病学组.经导管主动脉瓣置换术中国专家共识.中国介入心脏病学杂志,2015,23(12):661-667.
[2]Binder RK,Rodés-Cabau J,Wood DA,et al.Transcatheter aortic valve replacement with the SAPIEN 3:a new balloon-expandable transcatheter heart valve.JACC Cardiovasc Interv,2013,6(3):293-300.
[3]Webb J,Gerosa G,Lefèvre T,et al.Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve.J Am Coll Cardiol,2014,64(21):2235-2243.
[4]Leon MB,Smith CR,Mack M,et al.PARTNER Trial Investigators.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.N Engl J Med,2010,363(17):1597-1607.
[5]Kodali S,Thourani VH,White J,et al.Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable,high-risk and intermediate-risk patients with aortic stenosis.Eur Heart J,2016,37(28):2252-2262.
[6]Wendler O,Schymik G,Treede H,et al.SOURCE 3 Registry:design and 30-day results of the European postapproval registry of the latest generation of the SAPIEN 3 transcatheter heart valve.Circulation,2017,135(12):1123-1132.
[7]Hahn RT,Pibarot P,Webb J,et al.Outcomes with post-dilation following transcatheter aortic valve replacement:the PARTNER Itrial(placement of aortic transcatheter valve).JACC Cardiovasc Interv,2014,7(7):781-789.
[8]Herrmann HC,Thourani VH,Kodali SK,et al.One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis.Circulation,2016,134(2):130-140.
[9]Husser O,Pellegrini C,Kessler T,et al.Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve.JACC Cardiovasc Interv,2016,9(3):244-254.
[10]Vahanian A,Urena M,Walther T,et al.Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3European approval trial.EuroIntervention,2016,12(2):e235-e243.
[2]Binder RK,Rodés-Cabau J,Wood DA,et al.Transcatheter aortic valve replacement with the SAPIEN 3:a new balloon-expandable transcatheter heart valve.JACC Cardiovasc Interv,2013,6(3):293-300.
[3]Webb J,Gerosa G,Lefèvre T,et al.Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve.J Am Coll Cardiol,2014,64(21):2235-2243.
[4]Leon MB,Smith CR,Mack M,et al.PARTNER Trial Investigators.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.N Engl J Med,2010,363(17):1597-1607.
[5]Kodali S,Thourani VH,White J,et al.Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable,high-risk and intermediate-risk patients with aortic stenosis.Eur Heart J,2016,37(28):2252-2262.
[6]Wendler O,Schymik G,Treede H,et al.SOURCE 3 Registry:design and 30-day results of the European postapproval registry of the latest generation of the SAPIEN 3 transcatheter heart valve.Circulation,2017,135(12):1123-1132.
[7]Hahn RT,Pibarot P,Webb J,et al.Outcomes with post-dilation following transcatheter aortic valve replacement:the PARTNER Itrial(placement of aortic transcatheter valve).JACC Cardiovasc Interv,2014,7(7):781-789.
[8]Herrmann HC,Thourani VH,Kodali SK,et al.One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis.Circulation,2016,134(2):130-140.
[9]Husser O,Pellegrini C,Kessler T,et al.Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve.JACC Cardiovasc Interv,2016,9(3):244-254.
[10]Vahanian A,Urena M,Walther T,et al.Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3European approval trial.EuroIntervention,2016,12(2):e235-e243.